LivaNova (LIVN) Expected to Announce Earnings on Tuesday

LivaNova (NASDAQ:LIVN) will likely be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect LivaNova to post earnings of $0.80 per share and revenue of $324.11 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

LivaNova Trading Up 0.1 %

Shares of NASDAQ:LIVN opened at $47.68 on Tuesday. The company has a market capitalization of $2.59 billion, a P/E ratio of 113.52 and a beta of 1.00. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a 52-week low of $43.15 and a 52-week high of $64.47. The company has a 50-day simple moving average of $48.30 and a 200 day simple moving average of $49.56.

Wall Street Analyst Weigh In

Several brokerages have recently commented on LIVN. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of LivaNova in a research report on Tuesday, January 28th. Robert W. Baird raised their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Mizuho cut their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, LivaNova presently has an average rating of “Buy” and a consensus price target of $69.17.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.27% of the stock is owned by insiders.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.